Sarcomatrix to Present its Latest Advancements in the Development of its Lead Drug Candidate, S-969
Sarcomatrix Therapeutics, a clinical-stage biotechnology company focused on revolutionizing treatments for muscle-related diseases, today announced its participation at the 2025 BIO CEO & Investor...
Upcoming Exon 44 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy
Exon 44 skipping therapies represent a promising area in the treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle weakness...
Russian Biotech Company Generium has Begun Clinical Trials of a Gene Therapy for Duchenne Muscular Dystrophy
Clinical studies for a therapy for Duchenne muscular dystrophy have begun at Sirius University and the Russian biotech business Generium. At a gathering at...
Cumberland Pharmaceuticals Announces Fantastic Results from Phase 2 FIGHT Duchenne Trial in DMD Heart Disease
Cumberland Pharmaceuticals, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase...
A Novel “Mini-CRISPR” Could Be More Successful at Editing the Dystrophin Gene
Several research groups have been attempting to create compact CRISPR systems that can fit into a single AAV vector while maintaining editing capabilities. The...